Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Zomedica Stock Skyrocketed More Than 100% Today

By Joe Tenebruso - Jan 11, 2021 at 2:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pet care company's new diagnostic platform could be a game changer.

What happened

Shares of Zomedica ( ZOM 1.33% ) soared on Monday, extending the veterinary health company's torrid gains in recent days. As of 1:30 p.m. EST, Zomedica's stock price was up 103%.

So what

Investors appear to be buying in ahead of Zomedica's upcoming launch of its Truforma point-of-care diagnostic platform for cats and dogs on March 30. Truforma's patent-protected system uses bulk acoustic wave (BAW) technology, which is said to be precise and reliable. 

An upwardly sloping digital chart.

Investors continued to bid up Zomedica's stock on Monday. Image source: Getty Images.

"It certainly is a pleasure to be able to deliver such good news for our shareholders, employees, partners, and, especially, the veterinarians whom we serve," CEO Robert Cohen said in November in a press release announcing the launch. "It is a credit to all of our employees and their laser focus on advancing Truforma over the last many months that we are able to move into this final phase as we approach the commercial availability of our first product."  

Now what

The pet market is surging during the pandemic, as work-from-home arrangements allow more people to adopt cats and dogs. Spending on pets, including food and veterinary care, reached a new high of $99 billion in the U.S. alone in 2020, according to the American Pet Products Association. Within this massive market, spending on diagnostic care is forecasted to rise from $1.7 billion in 2019 to $2.8 billion in 2024. 

To meet the expected strong demand for its new diagnostic platform, Zomedica is ramping up its sales capabilities ahead of Truforma's upcoming commercial launch. Notably, Zomedica has made Truforma capable of being installed remotely, which should help to boost sales, by making installations easier and safer during the COVID-19 crisis. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
ZOM
$0.38 (1.33%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.